Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    -- Virtual Education Program: 2019 Edition


    Presentations from the COLT Meeting 2019

    We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.

    Timothy Hughes

    David Yeung 3 Devendra Hiwase

    Session 1: CML therapy - state of science
    Chair: Prof. Tim Hughes

    • Frontline Therapy for CML 
      (Prof Tim Hughes)
    • When frontline therapy fails
      (Dr David Yeung)
    • CML - Beyond chronic phase
      (Dr Devendra Hiwase)



    Timothy Hughes



    Frontline Therapy for CML
    Prof. Tim Hughes, SAHMRI / University of Adelaide

    • Consensus and controversies  in frontline therapy for CML
    • Relative risk of CML patients according to clinical and haematological data at diagnosis
    • Heterogeneity of response to TKI therapy in CML
    • Risk-adapted/goal specific treatment schema
    • Frontline therapy selection
    • Results from the TIDEL II trial in Australia/NZ
    • Future of CML management: Bioassay and molecular dynamics driven
    • Conclusions


    David Yeung 3  

    When frontline therapy fails
    Dr David Yeung - SAHMRI / Royal Adelaide Hospital

    • LASOR/DASCERN - failure to achieve 2019 ELN goals
    • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
    • ENESTCmr - failure to achieve deep molecular response
    • Ponatinib - drug of last resort
    • Asciminib (ABL001) - rising star?

    Devendra Hiwase


    CML - Beyond chronic phase
    Dr Devendra Hiwase - SA Pathology / Royal Adelaide Hospital

    • Diagnostic and management issues in CML-AP
      • Definitions of accelerated phase
      • Staging of chronic myeloid leukemia in the imatinib era
      • Survival benefit with Imatinib in CML-AP
      • Study results on NIL and DAS in patients with CML-AP
      • Imatinib vs. allogeneic SCT in CML-AP patients
      • Treatment strategy recommendations for CML-AP
      • Patient case
    • Diagnostic criteria and management of blast crisis
      • Transformation to blast crisis
      • Survival of CML-BC patients: German CML studies I to IIIA
      • Outcome of blast crisis in the era of TKI therapy
      • Cytogenetic landscape and impact in blast phase of CML in the era of TKI therapy
      • Management issues in CML-BC
      • IM and 2nd generation TKI's in BC patients
      • Patient case